Analysts give Arena's Belviq thumbs down in Japan

Handicapping Arena Pharmaceuticals' new weight-loss pill is a spectator sport. Since the small drugmaker ($ARNA) won approval for its Belviq drug, analysts in the U.S. have been weighing in about the drug's prospects. Now, analysts in Japan have added their two cents--and they're none too hopeful that Belviq will deliver the goods for Arena's Japanese marketing partner Eisai. Story

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.